Other substances

C135-LS/C121-LS

An anti-RBD (SARS-CoV-2 spike protein) antibody combination.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

C135-LS/C121-LS is a combination of two human monoclonal antibodies targeting RBD of the SARS-CoV-2 spike protein, both with LS mutation increasing their half-life (Schäfer et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Spike protein Animal model Antibody 		hAce2-HT1080 cells; muAce2-HT1080 cells; BALB/c mice; mouse-adapted SARS-CoV-2; Syrian hamsters; live SARS-CoV-2 (hamsters) 11.74

At higher dose (16 mg/kg) provided sterilizing effect in mice infected with mouse-adapted SARS-CoV-2.

 Nov/19/2020
Export (.csv)